• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

    6/22/23 4:36:44 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CELU alert in real time by email
    SC 13D/A 1 brhc20054760_sc13da.htm SC 13D/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    Celularity Inc.
    (Name of Issuer)

    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    151190105
    (CUSIP Number)

    c/o Tan Kong Han
    Dragasac Limited
    25th Floor, Wisma Genting, Jalan Sultan Ismail, 50250
    Kuala Lumpur, Wilayah Persekutuan, Malaysia
    +(603) 2333-6888
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 20, 2023
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 151190105
    Page 2 of 7 Pages
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Dragasac Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Isle of Man
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    36,592,597 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    36,592,597 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    36,592,597 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    19.6% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    1. This amount includes 6,529,818 Common Shares that the Reporting Person has the right to acquire upon exercise of Warrants (as defined in the Original Schedule 13D).
    2. Calculation is based on the sum of (i) 180,530,272 Common Shares outstanding as of May 18, 2023, as reported in the quarterly report on Form 10-Q filed by the Issuer on May 22, 2023, plus (ii) 6,529,818 Common Shares issuable to the Reporting Person upon exercise of Warrants, which have been added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 151190105
    Page 3 of 7 Pages
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Genting Berhad
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Malaysia
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    39,592,597 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    39,592,597 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    39,592,597 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    20.8% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO, HC
     
     
     
     
    1. This amount includes (i) 6,529,818 Common Shares that Dragasac Limited has the right to acquire upon exercise of Warrants (as defined herein) and (ii) 3,000,000 Common Shares that Resorts World Inc Pte. Ltd. has the right to acquire upon exercise of the RWI Warrant (as defined herein).
    2. Calculation is based on the sum of (i) 180,530,272 Common Shares outstanding as of May 18, 2023, as reported in the quarterly report on Form 10-Q filed by the Issuer on May 22, 2023, plus (ii) 6,529,818 Common Shares issuable to Dragasac Limited upon exercise of Warrants, and (iii) 3,000,000 Common Shares issuable to Resorts World Inc Pte. Ltd. upon exercise of the RWI Warrant, each of (ii) and (iii) having been added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 151190105
    Page 4 of 7 Pages
     
    1
    NAMES OF REPORTING PERSONS
     
     
    Lim Kok Thay
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Malaysia
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    415,357
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    39,592,597 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    415,357
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    39,592,597 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    40,007,954 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    21.0% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     
    1. This amount includes (i) 6,529,818 Common Shares that Dragasac Limited has the right to acquire upon exercise of Warrants (as defined herein) and (ii) 3,000,000 Common Shares that Resorts World Inc Pte. Ltd. has the right to acquire upon exercise of the RWI Warrant.
    2. Calculation is based on the sum of (i) 180,530,272 Common Shares outstanding as of May 18, 2023, as reported in the quarterly report on Form 10-Q filed by the Issuer on May 22, 2023, plus (ii) 6,529,818 Common Shares issuable to Dragasac Limited upon exercise of Warrants, (iii) 3,000,000 Common Shares issuable to Resorts World Inc Pte. Ltd. upon exercise of the RWI Warrant, and (iv) an aggregate 415,357 Common Shares issuable to the Reporting Person upon exercise of a deferred compensation award, exercise of stock options, or vesting of restricted stock units (as described further in Item 5 herein), each of (ii), (iii), and (iv) having been added to the Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.


    CUSIP No. 151190105
    Page 5 of 7 Pages
     
    EXPLANATORY NOTE
     
    Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 1 to the Schedule 13D (“Amendment No. 1”) amends certain items of the Schedule 13D filed with the Commission on July 26, 2021 (the “Original Schedule 13D”), relating to the Class A Common Stock, par value $0.0001 per share (the “Common Shares”), of Celularity, Inc. (the “Issuer”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
     
    Item 4.
    Purpose of Transaction
     
    Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows:
     
    On May 16, 2023, the Issuer entered into a senior secured loan agreement (the “Loan Agreement”) with Resorts World Inc Pte. Ltd. (“RWI”), pursuant to which RWI provided a loan to the Issuer (the “Original Loan”) in the aggregate principal amount of $6.0 million net of an original issue discount amount equal to $120,000. On June 20, 2023, the Issuer and RWI entered into an Amended and Restated Loan Agreement (the “Amended Loan Agreement”), pursuant to which RWI provided an additional loan to the Issuer (the “Additional Loan” and, together with the Original Loan, the “RWI Loan”) in the principal amount of $6.0 million net of an original issue discount amount equal to $678,000, for an aggregate principal amount of $12.0 million for the RWI Loan. The RWI Loan bears interest at a rate of 12.5% per year, with the first year of interest being paid in kind on the last day of each month, and matures March 17, 2025. RWI is a private company based in Singapore that is indirectly co-owned by each of Lim Kok Thay and Genting Berhad.
     
    In connection with the Additional Loan, on June 20, 2023, the Issuer granted RWI a warrant to purchase up to 3,000,000 Common Shares (the “RWI Warrant”) at a purchase price of $375,000, or $0.125 per whole Common Share underlying the RWI Warrant. The RWI Warrant is exercisable at an exercise price of $0.81 (and can be exercised on a cashless basis), and expires on the five (5) year anniversary of the date of issuance (or June 20, 2028).
     
    The foregoing summary of each of the Loan Agreement, the Amended Loan Agreement, and the RWI Warrant does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Loan Agreement and the Amended Loan Agreement and the form of RWI Warrant, each of which is attached hereto as exhibits to this Amendment No. 1 and is incorporated by reference.
     
    Item 5.
    Interest in Securities of the Issuer
     
    Item 5(a)-(c) of the Original Schedule 13D is hereby amended and supplemented as follows:
     
    (a)-(b) As of the date hereof, Dragasac may be deemed to beneficially own 36,592,597 Common Shares, or approximately 19.6% of the Common Shares outstanding. This amount includes (i) 30,062,779 Common Shares held directly by Dragasac and (ii) 6,529,818 Common Shares that Dragasac has the right to acquire upon exercise of Warrants.
     
    As of the date hereof, Genting Berhad may be deemed to beneficially own 39,592,597 Common Shares, or approximately 20.8% of the Common Shares outstanding. This amount includes (i) 30,062,779 Common Shares held directly by Dragasac, (ii) 6,529,818 Common Shares that Dragasac has the right to acquire upon exercise of Warrants, and (iii) 3,000,000 Common Shares that Resorts World Inc Pte. Ltd. has the right to acquire upon exercise of the RWI Warrant.
     
    As of the date hereof, Mr. Lim may be deemed to beneficially own 40,007,954 Common Shares, or approximately 21.0% of the Common Shares outstanding. This amount includes (i) 30,062,779 Common Shares held directly by Dragasac, (ii) 6,529,818 Common Shares that Dragasac has the right to acquire upon exercise of Warrants, (iii) 3,000,000 Common Shares that Resorts World Inc Pte. Ltd. has the right to acquire upon exercise of the RWI Warrant, (iv) 269,007 Common Shares underlying a deferred compensation award issued to Mr. Lim, with an exercise price of $3.83 and an expiration date of March 24, 2031, which is currently exercisable, (v) 56,053 Common Shares that Mr. Lim has the right to acquire upon exercise of a stock option award issued to Mr. Lim, with an exercise price of $6.72 and an expiration date of September 9, 2031, which is currently exercisable, (vi) 36,145 Common Shares underlying restricted stock units awarded to Mr. Lim, which are currently exercisable, subject to Mr. Lim’s continuous service with the Issuer, and (vii) 54,152 Common Shares that Mr. Lim has the right to acquire upon exercise of a stock option award issued to Mr. Lim, with an exercise price of $4.15 and an expiration date of July 13, 2032, which is currently exercisable, subject to Mr. Lim’s continuous service with the Issuer. This amount excludes (i) 199,921 Common Shares underlying restricted stock units awarded to Mr. Lim on June 14, 2023, and (ii) 277,778 Common Shares that Mr. Lim has the right to acquire upon exercise of a stock option award issued to Mr. Lim on June 14, 2023, with an exercise price of $0.7503 and an expiration date of June 14, 2033, because each of (i) and (ii) is not exercisable within sixty days of the date hereof.
     

    CUSIP No. 151190105
    Page 6 of 7 Pages
     
    The percentages set forth herein are based on the sum of (i) 180,530,272 Common Shares outstanding as of May 18, 2023, as reported in the quarterly report on Form 10-Q filed by the Issuer on May 22, 2023, plus the number of Common Shares issuable to each Reporting Person within sixty days, which Common Shares have been added to the total Common Shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act.
     
    Each of the Reporting Persons may be deemed to share the power to vote or direct the vote, and share the power to dispose or direct the disposition of, the 30,062,779 Common Shares held directly by Dragasac and the 6,529,818 Common Shares that Dragasac has the right to acquire upon exercise of Warrants. Each of Genting Berhad and Mr. Lim may further be deemed to share the power to vote or direct the vote, and share the power to dispose or direct the disposition of, the 3,000,000 Common Shares that RWI has the right to acquire upon exercise of the RWI Warrant. Mr. Lim may be deemed to have the sole power to vote or direct the vote, and the sole power to dispose or direct the disposition of, the aggregate 415,357 Common Shares issuable to Mr. Lim upon exercise of a deferred compensation award, exercise of stock options, or vesting of restricted stock units, as described herein.
     
    (c) The response to Item 4 is incorporated by reference herein. Other than as disclosed herein, the Reporting Persons have not effected any transactions in the Common Shares during the past sixty days.
     
    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
     
    Item 6 of the Original Schedule 13D is hereby amended and supplemented as follows:
     
    The response to Item 4 of this Amendment No. 1 is incorporated by reference herein.
     
    Except as otherwise set forth in the Schedule 13D, as amended by this Amendment No. 1, there are no contracts, arrangements, understandings, or relationships between the Reporting Persons named in Item 2 and any other person with respect to any securities of the Issuer, including but not limited to transfer or voting of any such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

    Item 7.
    Material to be Filed as Exhibits
     
    Item 7 of the Original Schedule 13D is hereby amended and supplemented as follows:
     
    Exhibit 99.5
    Form of Loan Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Issuer with the SEC on May 16, 2023)
       
    Exhibit 99.6
    Form of Amended Loan Agreement (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by the Issuer with the SEC on June 21, 2023)
       
    Exhibit 99.7
    Form of RWI Warrant (incorporated by reference to Exhibit 10.2 to the Form 8-K filed by the Issuer with the SEC on June 21, 2023)


    CUSIP No. 151190105
    Page 7 of 7 Pages
     
    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  June 22, 2023

     
    Dragasac Limited
     
           
     
    By:
    /s/ Tan Kong Han
     
     
    Name:
    Tan Kong Han
     
     
    Title:
    Director
     
         
     
    Genting Berhad
     
           
     
    By:
    /s/ Loh Bee Hong, Elaine
     
     
    Name:
    Loh Bee Hong, Elaine
     
     
    Title:
    Company Secretary
     
         
     
    Lim Kok Thay
     
         
     
    /s/ Lim Kok Thay
     
         



    Get the next $CELU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CELU

    DatePrice TargetRatingAnalyst
    1/30/2023$5.00 → $1.00Equal-Weight → Underweight
    Morgan Stanley
    12/22/2022Outperform → Perform
    Oppenheimer
    6/22/2022$15.00Buy
    H.C. Wainwright
    4/6/2022$10.00Buy → Hold
    Truist
    1/28/2022$9.00Outperform
    Oppenheimer
    11/24/2021$9.00Equal-Weight
    Morgan Stanley
    10/19/2021$12.00Buy
    Truist Securities
    More analyst ratings

    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres., Functional Regeneration Brigido Stephen converted options into 820 shares and covered exercise/tax liability with 268 shares, increasing direct ownership by 7% to 8,921 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:29 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Hariri Robert J converted options into 3,281 shares and covered exercise/tax liability with 1,154 shares, increasing direct ownership by 12% to 20,328 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:27 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beers David C converted options into 1,025 shares and covered exercise/tax liability with 360 shares, increasing direct ownership by 4% to 18,201 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      4/15/25 4:30:24 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Leadership Updates

    Live Leadership Updates

    See more
    • Celularity Appoints Richard J. Berman to its Board of Directors

      FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol

      8/28/24 4:45:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

      FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera

      9/7/23 4:10:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Paul Graves as Chief Communications Officer

      FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C

      1/4/23 4:10:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Celularity Inc.

      10-K/A - Celularity Inc (0001752828) (Filer)

      5/21/25 5:29:45 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

      8-K - Celularity Inc (0001752828) (Filer)

      5/20/25 4:52:15 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Inc. filed SEC Form 8-K: Leadership Update

      8-K - Celularity Inc (0001752828) (Filer)

      5/16/25 4:15:38 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Financials

    Live finance-specific insights

    See more
    • Celularity Provides Corporate Update

      FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi

      10/22/24 8:30:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

      SC 13D/A - Celularity Inc (0001752828) (Subject)

      3/15/24 5:32:04 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celularity Inc. (Amendment)

      SC 13G/A - Celularity Inc (0001752828) (Subject)

      2/8/24 6:00:11 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Celularity Inc. (Amendment)

      SC 13D/A - Celularity Inc (0001752828) (Subject)

      1/17/24 5:15:41 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Announces Full Year 2024 Operating and Financial Results

      FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. "We built momentum through 2024 and ended the year with a strong finish, as reflected in higher net revenues from the sale of our commercial-stage advanced biomaterial products," said Dr. Robert Hariri, M.D., Ph.D., CEO and Chairman. "Sales growth was notably strong for our Biovance® product line, which we believe will continue to contribute to an improving revenue outlook for the next several quarters. We were also extremely pleased to receive

      5/9/25 9:15:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

      FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250(f) and accordingly the Company will be delisted unless it appeals this determination. The Company's past due fee balance totaled $70,000. On April 25, 2025, the Company paid in full the fee balance owed to Nasdaq. Additionally, on April 16, 2024, Nasdaq notified the Company that it is delinquent in filing its Form 10-K for the year ended December 31, 2024, and therefore, does not comply with Listing Rule 5250(c)(

      4/25/25 5:30:00 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

      FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date of the Medicare Local Coverage Determination, or LCD, titled "Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers" first published in November 2024. An LCD is a determination by a Medicare Administrative Contractor, or MAC, whether to cover a particular service on a MAC-wide, basis. A MAC processes Medicare Part A and Part B claims for a d

      4/14/25 8:00:00 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lim Kok Thay bought $5,331,335 worth of shares (21,410,983 units at $0.25) (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      1/17/24 5:22:20 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hariri Robert J bought $2,984,294 worth of shares (18,422,124 units at $0.16), increasing direct ownership by 182% to 28,570,434 units (SEC Form 4)

      4 - Celularity Inc (0001752828) (Issuer)

      10/10/23 9:48:11 PM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously

      1/30/23 7:11:17 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity downgraded by Oppenheimer

      Oppenheimer downgraded Celularity from Outperform to Perform

      12/22/22 7:40:17 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Celularity with a new price target

      H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00

      6/22/22 7:19:25 AM ET
      $CELU
      Biotechnology: Pharmaceutical Preparations
      Health Care